2011 Vol.29, N°5 - Suppl.68 - Table of contents

Low-dose Glucocorticoids in Rheumatic Diseases

Guest Editors: J.W.J. Bijlsma, J. Braun, F. Buttgereit, M. Cutolo, T. Pincus

Editorial

CER5080
2011,29,5,Suppl.68
Pg. 0002-0004

Free to view

Low-dose glucocorticoids in rheumatic diseases: introduction
T. Pincus, J.W. Bijlsma, J. Braun, F. Buttgereit, M. Cutolo

Full Papers

CER5006
2011,29,5,Suppl.68
Pg. 0005-0012

Free to view

History of the development of corticosteroid therapy.
T.G. Benedek

CER4954
2011,29,5,Suppl.68
Pg. 0013-0018

Free to view

Pharmacodynamics of glucocorticoids
C. Strehl, C.M. Spies, F. Buttgereit

CER5013
2011,29,5,Suppl.68
Pg. 0019-0022

Free to view

Regulation of glucocorticoids by the central nervous system
M. Cutolo, F. Buttgereit, R.H. Straub

CER5081
2011,29,5,Suppl.68
Pg. 0023-0031

Free to view

Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases – a role for misguided energy regulation
R.H. Straub, F. Buttgereit, M. Cutolo

CER5082
2011,29,5,Suppl.68
Pg. 0032-0041

Free to view

Glucocorticoid receptor: implications for rheumatic diseases
T. Kino, E. Charmandari, G.P. Chrousos

CER4953
2011,29,5,Suppl.68
Pg. 0042-0045

Free to view

Prednisone chronotherapy
C.M. Spies, M. Cutolo, R.H. Straub, G.R. Burmester, F. Buttgereit

Brief Papers

CER5011
2011,29,5,Suppl.68
Pg. 0046-0051

Free to view

The COBRA trial 20 years later
M. Boers

CER5083
2011,29,5,Suppl.68
Pg. 0052-0058

Free to view

The origins, results and consequences of the 1995 Arthritis Research Campaign Low-Dose Glucocorticoid Study.
J. Kirwan

CER4949
2011,29,5,Suppl.68
Pg. 0059-0062

Free to view

Glucocorticoids in rheumatoid arthritis: lessons from the Utrecht study
J. Jacobs, J. Bijlsma

CER5084
2011,29,5,Suppl.68
Pg. 0063-0067

Free to view

Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA
B. Svensson, I. Hafström

CER5085
2011,29,5,Suppl.68
Pg. 0068-0072

Free to view

A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial
S. Wassenberg, R. Rau, H. Zeidler

CER5086
2011,29,5,Suppl.68
Pg. 0073-0076

Free to view

The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial
T. Pincus

CER5088
2011,29,5,Suppl.68
Pg. 0077-0080

Free to view

Rheumatoid arthritis and glucocorticoids; the contribution of a literature search to the development of a EULAR recommendation on treatment with glucocorticoids in RA
S.L. Gorter

Review

CER4950
2011,29,5,Suppl.68
Pg. 0081-0084

Free to view

Glucocorticoids in rheumatology: indications and routes of administration
J. Jacobs, J. Bijlsma

CER4957
2011,29,5,Suppl.68
Pg. 0085-0092

Free to view

Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis
N.A. Smits, N. Duru, J.W. Bijlsma, J.W. Jacobs

CER4719
2011,29,5,Suppl.68
Pg. 0093-0098

Free to view

Glucocorticoid-induced osteoporosis
D. Den Uyl, I.E. Bultink, W.F. Lems

CER5089
2011,29,5,Suppl.68
Pg. 0099-0103

Free to view

Safety of glucocorticoids – clinical trials
J.A.P. Da Silva

CER5090
2011,29,5,Suppl.68
Pg. 0104-0112

Free to view

The safety of low-dose glucocorticoids in rheumatic diseases
Y.G. Hwang, K. Saag

CER5091
2011,29,5,Suppl.68
Pg. 0113-0115

Free to view

Low–dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis
O. Malysheva, C.G. Baerwald

CER4948
2011,29,5,Suppl.68
Pg. 0116-0120

Free to view

Toward safer treatment with glucocorticoids: via patient and rheumatologist perspectives to recommendations on monitoring for adverse events
M.C. Van Der Goes, J. Jacobs, J. Bijlsma

Paediatric Rheumatology

CER4951
2011,29,5,Suppl.68
Pg. 0121-0125

Free to view

Glucocorticoid treatment in early rheumatoid arthritis
D. Krause, R. Rau, J. Braun

CER5092
2011,29,5,Suppl.68
Pg. 0126-0129

Free to view

Glucocorticoids in systemic lupus erythematosus
M. Mosca, C. Tani, L. Carli, S. Bombardieri

CER5095
2011,29,5,Suppl.68
Pg. 0130-0138

Free to view

Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: Personal experience over 25 years
T. Pincus, I. Castrejón, T. Sokka

CER5094
2011,29,5,Suppl.68
Pg. 0139-0142

Free to view

Glucocorticoid treatment in spondyloarthritis
C. Fendler, X. Baraliakos, J. Braun

CER5012
2011,29,5,Suppl.68
Pg. 0143-0147

Free to view

Glucocorticoid treatment of polymyalgia rheumatica
R. Caporali, M.A. Cimmino, C. Montecucco, M. Cutolo

CER4952
2011,29,5,Suppl.68
Pg. 0148-0152

Free to view

Glucocorticoids in paediatric rheumatology
A. Ravelli, B. Lattanzi, A. Consolaro, A. Martini